SCHEMBL4264699

SCHEMBL4264699

COc1ccc(Cl)c(-c2cc(C)c3nc(N)nnc3c2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 15/20 0.70
▸ HSP90AA1 P07900 1/20 0.48
▸ HSP90AB1 P08238 1/20 0.48
▸ ABL1 P00519 2/20 0.43
▸ PDE2A O00408 4/20 0.42
▸ PDE10A Q9Y233 4/20 0.42
▸ PDGFRB P09619 3/20 0.42
▸ CIT O14578 1/20 0.41
▸ GAK O14976 1/20 0.41
▸ EPHB6 O15197 1/20 0.41
▸ RIPK2 O43353 1/20 0.41
▸ PRKD3 O94806 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ YES1 P07947 1/20 0.41
▸ RET P07949 1/20 0.41
▸ BCR P11274 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ EPHA2 P29317 1/20 0.41
▸ EPHB2 P29323 1/20 0.41
▸ TYK2 P29597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4273050 0.89 SRC (0.57) SRCHSP90AA1HSP90AB1PDE2APDE10A
SCHEMBL13609499 0.87 SRC (0.59) SRCHSP90AA1HSP90AB1ABL1PDE2A
SCHEMBL13609505 0.85 SRC (0.53) SRCHSP90AA1HSP90AB1
SCHEMBL15095263 0.85 SRC (0.77) SRCABL1PDGFRB
SCHEMBL4265952 0.82 SRC (1.00) SRCABL1PDGFRBYES1KDR
SCHEMBL13609478 0.79 SRC (0.69) SRCPDGFRBYES1
SCHEMBL4270715 0.78 SRC (0.57) SRCHSP90AA1HSP90AB1ABL1
SCHEMBL4273466 0.78 SRC (0.66) SRCABL1PDGFRBYES1KDR
SCHEMBL4264367 0.78 DHFR (0.50) SRCHSP90AA1HSP90AB1PDE2APDE10A
SCHEMBL4265924 0.77 SRC (0.67) SRCPDGFRBYES1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 — — EP disclosed
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 — — EP disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 — — US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 — — US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 — — US disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 — — EP disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 — — EP disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 — — US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 — — US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 — — US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 — — US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 — — US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 — — US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 — — US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 — — US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 — — US disclosed
EP-1809614-A2 BENZOTRIAZINE INHIBITORS OF KINASES Targegen, Inc. (US) 2007-07-25 — — EP disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 — — US disclosed
WO-2005096784-A2 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES SRC, CAMK4, CAMK2G SRC 1/4885HSP90AA1 1740/4885HSP90AB1 1465/4885
US-20090275569-A1 Benzotriazine Inhibitors of Kinases SRC, CAMK4, CAMK2G SRC 1/4885HSP90AA1 1740/4885HSP90AB1 1465/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G SRC 1/4885HSP90AA1 1740/4885HSP90AB1 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback